New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
08:40 EDTALXNAlexion gets positive CHMP opinion on extended indication for eculizumab
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Soliris. The marketing authorization holder for this medicinal product is Alexion Europe SAS. Soliris is currently authorized for the treatment of paroxysmal nocturnal haemoglobinuria in adults only and atypical haemolytic uremic syndrome in adults and children. The CHMPís opinion now recommends that the PNH indication be extended to include children, the EMA announced.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
05:28 EDTALXNAlexion receives approval for updates to EU label for Solaris
Subscribe for More Information
April 7, 2015
17:38 EDTALXNAlexion CEO Dr. Leonard Bell retired as of March 31
Dr. Leonard Bell, the principal founder and CEO of Alexion Pharmaceuticals retired from Alexion effective March 31, after serving as CEO for twenty-three years. No severance was paid to Dr. Bell in connection with his retirement. On April 1, Alexion entered into a Consulting Agreement and a Letter Agreement with Dr. Bell. Dr. Bell continues to serve as Alexion's Chairman of the Board of Directors.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use